Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00231387
Status:
COMPLETED
Last Update Posted:
2017-01-23
First Post:
2005-10-03
Brief Title:
Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Rosiglitazone and Plaque Study A 12 Month Randomised Double-blind Placebo-controlled Magnetic Resonance Imaging Study to Evaluate the Effect of Rosiglitazone on the Structure and Composition of Carotid Atherosclerotic Plaques in Subjects With Type 2 Diabetes Mellitus and Coexisting Vascular Disease or Hypertension
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase IIIb randomised double blind placebo controlled study in patients with type 2 diabetes mellitus and coexisting vascular disease or hypertension The total duration of the study will be approximately 60 weeks The aim of this study is to examine the potential beneficial effects of rosiglitazone on carotid atheroma in patients with type 2 diabetes mellitus and coexisting vascular disease or hypertension It is hypothesised that treatment with rosiglitazone will lead to an decrease in plaque size In addition it is hoped that rosiglitazone will have a positive effect on plaque composition and stability
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None